Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has granted fast track designation to elticertinib, a targeted oral therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who've already tried chemotherapy and amivantamab. Early trial data showed a 54% overall response rate at doses of 360 mg or higher. The designation aims to speed up development for a patient population with limited effective treatment options.
The FDA has granted fast track designation to elticertinib (PFL-721; STX-721), an investigational oral therapy targeting EGFR exon 20 insertion mutations in adults with locally advanced or metastatic NSCLC who have progressed after both platinum-based chemotherapy and amivantamab. This mutation subtype has historically been difficult to treat, with patients facing limited efficacy and tolerability challenges from available options.
Elticertinib is an irreversible tyrosine kinase inhibitor (TKI) engineered to selectively target mutant EGFR and HER2 receptors while sparing wild-type EGFR — a design intended to improve the tolerability profile. Preclinical studies showed selective inhibition of mutant receptors and tumor regression in xenograft models, supporting its advancement into human trials.
By the Numbers:
Why it matters: For EGFR exon 20 insertion–mutated NSCLC patients who've exhausted first-line options, effective therapies remain scarce. The fast track designation will allow closer FDA collaboration to accelerate elticertinib's development, potentially bringing a more targeted and better-tolerated option to a population with significant unmet need.